A longer waiting game: Bridging children to heart transplant with the Berlin Heart EXCOR device—the United Kingdom experience

Cassidy, Jane; Dominguez, Troy E.; Haynes, Simon; Burch, Michael; Kirk, Richard; Hoskote, Aparna; Smith, Jon; Fenton, Matthew; Griselli, Massimo; Hsia, Tain Yen; Ferguson, Lee P.; Doorn, Carin van; Hasan, Asif; Karimova, Ann

doi:10.1016/j.healun.2013.08.003

Cited by 67 publications

(54 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3b, c). The inner diameter of the cuff and the diameter of the outflow graft of the DuraHeart and Nipro LVAD are the same size, providing advantages when exchanging these devices [13].…”

Section: Surgical Techniquementioning

confidence: 99%

“…Considering the long waiting time for patients who have already undergone implantation with a Nipro LVAD, we believe that conversion to an implantable continuous-flow device will provide a safer bridge to transplantation and promises higher quality of life. We have now converted eight patients (four males and four females) from a Nipro paracorporeal LVAD to a DuraHeart device [13]. In those Fig.…”

Section: Future Perspectives Of the Duraheart And Hvad In Japanmentioning

confidence: 99%

“…In Japan, the Nipro LVAD (Nipro, Osaka, Japan) is the only available paracorporeal pneumatic device [10,11]. Currently, this device is still used for biventricular support or pediatric patients weighing up to 20 kg after the introduction of an implantable device [12,13].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Current status of third-generation implantable left ventricular assist devices in Japan, Duraheart and HeartWare

Sawa

2014

Surg Today

View full text Add to dashboard Cite

Recently, left ventricular assist devices (LVADs) have become a viable therapeutic approach as a bridge to cardiac transplantation, as well as destination therapy or as part of the bridge to recovery. In Japan, paracorporeal pneumatic devices are the only choice for such therapy, as implantable LVADs are not yet generally available due to device lag, which represents a serious problem in this field. Clinical trials of four different continuous-flow pumps, both axial and centrifugal flow types, were completed at about the same time, and two of those devices, DuraHeart and EVAHEART, have already been approved for use in Japan. Thus, reports of advanced treatment for severe heart failure with these devices are expected. The DuraHeart (Terumo Heart, Ann Arbor, MI, USA) and another device named the HeartWare (HeartWare Inc, Miami Lakes, FL, USA) are so-called third-generation devices, as they have achieved miniaturization and improvements in performance from the use of magnetic levitation. Based on our experiences from both clinical research and experimental use, we herein discuss the DuraHeart and HeartWare devices, with a focus on the clinical outcomes and management strategies. Because of the long waiting period for heart transplantation in Japan, these two devices are considered to have important roles in the near future for the treatment of severe heart failure, and a comprehensive strategy for LVAD therapy including such third-generation implantable devices is expected.

show abstract

“…3b, c). The inner diameter of the cuff and the diameter of the outflow graft of the DuraHeart and Nipro LVAD are the same size, providing advantages when exchanging these devices [13].…”

Section: Surgical Techniquementioning

confidence: 99%

Section: Future Perspectives Of the Duraheart And Hvad In Japanmentioning

confidence: 99%

See 1 more Smart Citation

Current status of third-generation implantable left ventricular assist devices in Japan, Duraheart and HeartWare

Sawa

2014

Surg Today

View full text Add to dashboard Cite

show abstract

“…3,4,10 However, early reports were notable for a high rate of neurological adverse events in pulsatile flow devices. 4,[11][12][13] Overall adverse event rates and types have not been described in detail at the national level. The objective of this manuscript is to provide the first contemporary, national-level description of the adverse events associated with the full spectrum of pediatric VAD use in the United States.…”

Section: Introductionmentioning

confidence: 99%

Adverse Events in Children Implanted With Ventricular Assist Devices in the US: Data From the Pediatric Interagency Registry for Mechanical Circulatory Support (PediMACS)

Rosenthal

Almond

Jacquiss

et al. 2015

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

show abstract

“…Similar to adult patients, VAD can be applied to pediatric patients, although there have been smaller device options available. The Berlin Heart EXCOR is one option, although it is still associated with thromboembolic and hemorrhagic events with high mortality (12)(13)(14). Therefore, other options are needed.…”

Section: Introductionmentioning

confidence: 99%

Direct Epicardial Assist Device using Artificial Rubber Muscle in a Swine Model of Pediatric Dilated Cardiomyopathy

et al. 2015

View full text Add to dashboard Cite

Direct epicardial assist device using artificial rubber muscle in a swine model of pediatric dilated cardiomyopathy. patients. The present study examined the hemodynamic effects of a direct cardiac compression device using circumferential artificial rubber muscles in a young swine model of dilated cardiomyopathy.Methods: Dilated cardiomyopathy was established in 6 pigs (6-8 weeks of rapid right ventricular pacing; average weight, 22.6 ± 2.1 kg). The device was designed using pneumatic rubber muscles (Fluidic Muscle, Festo).Hemodynamic parameters were monitored under baseline conditions, after the assistance, and after inducing ventricular fibrillation. Hemodynamic data were acquired using a PiCCO, multilumened thermodilution catheter in the pulmonary artery, left ventricular pressure monitoring, and epicardial echocardiography.Results: Direct epicardial assistance resulted in a significant improvement in hemodynamic data. Cardiac output improved from 1.39 ± 0.24 L/min to 1.96 ± 0.46 (p = 0.02). Stroke volume (14.5 ± 3.2 mL versus 20.1 ± 4.3 ml, p<0.01) and ejection fraction (25.2 ± 3.6% versus 47.7 ± 7.8%, p<0.01) also improved after assistance. After inducing ventricular fibrillation, cardiac output was maintained at 1.33 ± 0.28 L/min.Conclusions: Use of a circumferential direct epicardial assistant device resulted in improvement in hemodynamic data in a dilated cardiomyopathy model. Although there is still a need for improvements in device components, the direct cardiac assist device may be a good alternative to recent heart failure device therapies.

show abstract

A longer waiting game: Bridging children to heart transplant with the Berlin Heart EXCOR device—the United Kingdom experience

Cited by 67 publications

References 13 publications

Current status of third-generation implantable left ventricular assist devices in Japan, Duraheart and HeartWare

Current status of third-generation implantable left ventricular assist devices in Japan, Duraheart and HeartWare

Adverse Events in Children Implanted With Ventricular Assist Devices in the US: Data From the Pediatric Interagency Registry for Mechanical Circulatory Support (PediMACS)

Direct Epicardial Assist Device using Artificial Rubber Muscle in a Swine Model of Pediatric Dilated Cardiomyopathy

Contact Info

Product

Resources

About